arrow
O

Oliver Sartor

university medical center hamburg—eppendorf
H指数:95
被引数:4.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer

前列腺特异性抗原和客观缓解分析在PROpel研究中:奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙作为转移性去势抵抗性前列腺癌的一线疗法

2025-11-040
OAAI
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

[177Lu]Lu-PSMA-617在有和无雄激素受体通路抑制剂联合使用情况下,在转移性去势抵抗性前列腺癌患者中的疗效

2025-08-050
PRE
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer

放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

2025-07-190
PRE
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial

局部高危前列腺癌的转录组学分析改善了预后判断,并确定了在NRG肿瘤学/RTOG 0521 III期试验中,将多西他赛添加到根治性放疗联合雄激素抑制治疗中获益。

2025-07-170
OAAI
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

[177Lu]Lu-PSMA-617与雄激素受体途径抑制剂变化的PSMAfore 3期试验在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的最终总生存期和安全性分析

2025-07-170
OAAI
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase Inhibitors

奥氮平用于管理抗血管生成酪氨酸激酶抑制剂所致的副作用

2025-05-030
PRE
Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]

勘误:“在III期VISION试验中,接受[177Lu]Lu-PSMA-617治疗的患者中,前列腺特异性抗原水平下降与临床结局的相关性”[Eur. Urol. 86 (2024) 552–562]

2025-04-080
OAAI
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
2024-12-020
OAAI
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

下降的前列腺特异性抗原水平与接受[177Lu]Lu-PSMA-617治疗的三期VISION试验中转移性去势抵抗性前列腺癌患者临床结局的关联

2024-12-010
OAAI
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

对患有生物化学复发和晚期前列腺癌的男性实施循证策略: 来自美国前列腺癌会议2024的共识建议

CANCER
IF5.1
2024-12-010
PRE
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617

接受 [177Lu]Lu- PSMA-617治疗的转移性去势抵抗性前列腺癌和肝转移患者的预后

2024-10-300
PRE
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial

奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙在无症状/轻度症状及症状性转移性去势抵抗性前列腺癌患者一线治疗中的有效性和安全性:来自III期PROpel试验的分析

2024-10-010
OAAI
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

NRG/RTOG 9902 3期试验中基于数字病理学的多模态人工智能架构的外部验证

2024-10-012
OA